Novel Biomarkers in Alzheimer’s Disease
Alzheimer's disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04966naaaa2201549uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_68362 | ||
| 005 | 20210501 | ||
| 020 | |a books978-3-03943-904-1 | ||
| 020 | |a 9783039439034 | ||
| 020 | |a 9783039439041 | ||
| 024 | 7 | |a 10.3390/books978-3-03943-904-1 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Villa, Chiara |4 edt | |
| 700 | 1 | |a Villa, Chiara |4 oth | |
| 245 | 1 | 0 | |a Novel Biomarkers in Alzheimer’s Disease |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (442 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Alzheimer's disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a critical need to establish biomarkers that can be used to detect AD in individuals before the onset of clinical signs and provide mitigating therapeutics. The aim of this Special Issue is to discuss the current knowledge as well as future perspectives on the role of biomarkers in the screening, diagnosis, treatment and follow-up of AD. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a flotillin | ||
| 653 | |a Alzheimer's disease | ||
| 653 | |a biomarker | ||
| 653 | |a exosomes | ||
| 653 | |a beta-amyloid | ||
| 653 | |a Tau | ||
| 653 | |a aging | ||
| 653 | |a biomarkers | ||
| 653 | |a cytokines | ||
| 653 | |a cognitive decline | ||
| 653 | |a metabolomics | ||
| 653 | |a neuroinflammation | ||
| 653 | |a multivariate analysis | ||
| 653 | |a physical performance | ||
| 653 | |a person-tailored | ||
| 653 | |a PET/CT | ||
| 653 | |a (18F)FDG | ||
| 653 | |a neuropsychological assessment | ||
| 653 | |a APP mutations | ||
| 653 | |a APOE alleles | ||
| 653 | |a PSEN1 | ||
| 653 | |a PSEN2 | ||
| 653 | |a germline mutations | ||
| 653 | |a late onset AD | ||
| 653 | |a early onset AD | ||
| 653 | |a familial AD | ||
| 653 | |a genetics of AD | ||
| 653 | |a mitochondrial spare respiratory capacity | ||
| 653 | |a mitochondrial | ||
| 653 | |a membrane potential | ||
| 653 | |a glycolytic reserve | ||
| 653 | |a semantic memory | ||
| 653 | |a phonemic fluency | ||
| 653 | |a episodic memory | ||
| 653 | |a neuropsychology | ||
| 653 | |a neuroimaging | ||
| 653 | |a Alzheimer's disease | ||
| 653 | |a mild cognitive impairment | ||
| 653 | |a EEG | ||
| 653 | |a TMS | ||
| 653 | |a obesity | ||
| 653 | |a diabetes | ||
| 653 | |a inflammation | ||
| 653 | |a Amyloid Beta | ||
| 653 | |a mitochondrial dysfunction | ||
| 653 | |a nutrition | ||
| 653 | |a omega-3 fatty acids | ||
| 653 | |a antioxidant | ||
| 653 | |a carotenoids | ||
| 653 | |a vitamin E | ||
| 653 | |a cognition | ||
| 653 | |a older adults | ||
| 653 | |a ageing | ||
| 653 | |a subjective cognitive decline | ||
| 653 | |a clock genes | ||
| 653 | |a Clock | ||
| 653 | |a ApoE | ||
| 653 | |a cardiovascular risk factors | ||
| 653 | |a Alzheimer disease | ||
| 653 | |a semantic priming | ||
| 653 | |a amyloid beta | ||
| 653 | |a cerebrospinal fluid | ||
| 653 | |a amyloid beta peptide | ||
| 653 | |a total tau | ||
| 653 | |a phosphorylated tau | ||
| 653 | |a diagnosis | ||
| 653 | |a drug development | ||
| 653 | |a clinical trials | ||
| 653 | |a diagnostic research | ||
| 653 | |a virus | ||
| 653 | |a bacteria | ||
| 653 | |a dementia | ||
| 653 | |a blood | ||
| 653 | |a behavioral and psychological symptoms of dementia (BPSD) | ||
| 653 | |a Alzheimer's disease (AD) | ||
| 653 | |a neuropsychiatry inventory scale (NPI) | ||
| 653 | |a endophenotypes | ||
| 653 | |a CART analysis | ||
| 653 | |a MTHFR | ||
| 653 | |a APOE | ||
| 653 | |a COMT | ||
| 653 | |a genetic variants | ||
| 653 | |a early diagnosis | ||
| 653 | |a biofluids | ||
| 653 | |a amyloid cascade hypothesis | ||
| 653 | |a glucose metabolism | ||
| 653 | |a adipose tissue dysfunction | ||
| 653 | |a energetic metabolism | ||
| 653 | |a lysosomes dysfunction | ||
| 653 | |a Type-3-Diabetes | ||
| 653 | |a neurodegeneration | ||
| 653 | |a amyloid | ||
| 653 | |a tau | ||
| 653 | |a soluble TREM2 | ||
| 653 | |a NfL | ||
| 653 | |a Multiplex | ||
| 653 | |a SiMoA | ||
| 653 | |a diagnostics | ||
| 653 | |a messenger RNA | ||
| 653 | |a microRNA | ||
| 653 | |a neurotropic microbes | ||
| 653 | |a precision medicine | ||
| 653 | |a prognostics | ||
| 653 | |a synaptic biomarkers | ||
| 653 | |a neurofilament light chain | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/3371 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/68362 |7 0 |z DOAB: description of the publication |